OBJECTIVE

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumour associated with poor 5-year survival. We aimed to determine factors which differentiate short and long-term survivors and identify a prognostic biomarker.

METHODS

Over a ten-year period, patients with resected PDAC who developed disease recurrence within 12 months (Group I) and those who had no disease recurrence for 24 months (Group II) were identified. Clinicopathological data was analysed. Ion Torrent high-throughput sequencing on DNA extracted from FFPE tumour samples was used to identify mutations. Additionally, peripheral blood samples were analysed for variants in cell-free DNA, circulating tumour cells (CTCs), and microRNAs.

RESULTS

Multivariable analysis of clinicopathological factors showed that a positive medial resection margin was significantly associated with short disease-free survival ( = 0.007). Group I patients ( = 21) had a higher frequency of the mutant mean variant allele (16.93% ± 11.04) compared to those in Group II ( = 13; 7.55% ± 5.76, = 0.0078). Group I patients also trended towards having a c.35G>A p.Gly12Asp mutation in addition to variants in other genes, such as , , and . Mutational status of cell-free DNA, and number of CTCs, was not found to be useful in this study. A circulating miRNA (hsa-miR-548ah-5p) was found to be significantly differentially expressed.

CONCLUSIONS

Medial resection margin status and the frequency of mutation in the tumour tissue are independent prognostic indicators for resectable PDAC. Circulating miRNA hsa-miR-548ah-5p has the potential to be used as a prognostic biomarker.